Cannabis as a Complementary Treatment in Multiple Sclerosis
Status:
Not yet recruiting
Trial end date:
2025-03-15
Target enrollment:
Participant gender:
Summary
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS)
afflicting over 77,000 Canadians. Unfortunately, the therapeutic arsenal to relieve MS
symptoms is limited. It is therefore essential to develop better approaches to treat the
symptoms of MS. The use of cannabis for recreational purposes is now legal in Canada.
However, for many years, people with Multiple Sclerosis (PwMS) have used cannabis either to
relax, to reduce pain and spasticity, or to improve sleep and daily functioning. Currently,
there is little scientifically established evidence that cannabis works on these symptoms in
people with MS. It is therefore important to carry out studies to better understand the
efficacy Δ-9-tetrahydrocannabinol (THC), and cannabidiol (CBD) on MS symptoms . THC is known
for its analgesic, neuroprotective and anti-inflammatory properties and CBD seems to have
positive effects on anxiety and cognitive abilities (memory, concentration).
For this study, investigators hypothesize that administering different doses of THC alone,
CBD alone, and THC and CBD combined will result in a significant beneficial effect on
spasticity relief compared to placebo.
Phase:
Phase 3
Details
Lead Sponsor:
Centre hospitalier de l'Université de Montréal (CHUM)
Collaborators:
Canadian Institutes of Health Research (CIHR) Multiple Sclerosis Society of Canada